RemeGen Co. Ltd. Class H (HK:9995)
:9995
Want to see HK:9995 full AI Analyst Report?
Top Page
RemeGen Co. Ltd. Class H
(9995)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$69.00
▼(-42.45% Downside)
Action:Reiterated
Date:06/09/26
The score is held back mainly by weak cash flow conversion and very bearish technicals (price below all key moving averages with negative MACD). Improved profitability and revenue momentum support the score, but a high P/E with no dividend yield adds valuation risk.
Positive Factors
Profitability turnaround
The company has moved from multi-year losses to sustained positive operating and net margins (~21.8%). Durable high margins signal pricing power or favorable cost structure, enabling internal funding for R&D and commercialization and improving long-term self-sufficiency if maintained.
Negative Factors
Weak cash conversion
Reported profits are not translating into cash: OCF/NI ~0.02 and only modest positive free cash flow in TTM after prior negative years. This undermines durability of earnings, constrains reinvestment or debt repayment capacity, and raises dependence on external financing over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability turnaround
The company has moved from multi-year losses to sustained positive operating and net margins (~21.8%). Durable high margins signal pricing power or favorable cost structure, enabling internal funding for R&D and commercialization and improving long-term self-sufficiency if maintained.
Read all positive factors
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$60.53B
Dividend YieldN/A
Average Volume (3M)6.34M
Price to Earnings (P/E)49.4
Beta (1Y)1.55
Revenue Growth80.08%
EPS GrowthN/A
CountryHK
Employees2,999
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.29
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.84
Price to Sales (P/S)11.22
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$129.32Price Target Upside7.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.45
Revenue Forecast (FY)HK$7.00B
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
Company Description
RemeGen Co., Ltd. is a biopharmaceutical firm dedicated to the innovation, advancement, and marketing of biologic therapies. The company targets critical unmet medical requirements in autoimmune, oncological, and ophthalmic diseases within Mainlan...
How the Company Makes Money
null...
RemeGen Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.35B | 3.17B | 1.72B | 1.08B | 767.77M | 1.42B |
| Gross Profit | 2.86B | 2.57B | 1.37B | 822.99M | 497.84M | 1.36B |
| EBITDA | 539.01M | 438.88M | -1.19B | -1.25B | -805.70M | 402.05M |
| Net Income | 1.27B | 709.65M | -1.47B | -1.51B | -997.84M | 276.26M |
Balance Sheet | ||||||
| Total Assets | 7.34B | 7.25B | 5.50B | 5.53B | 6.02B | 4.16B |
| Cash, Cash Equivalents and Short-Term Investments | 2.74B | 2.42B | 759.53M | 709.07M | 2.19B | 1.76B |
| Total Debt | 2.09B | 2.20B | 2.67B | 1.26B | 165.03M | 102.78M |
| Total Liabilities | 3.43B | 3.55B | 3.51B | 2.09B | 1.04B | 712.79M |
| Stockholders Equity | 3.92B | 3.61B | 1.99B | 3.44B | 4.98B | 3.45B |
Cash Flow | ||||||
| Free Cash Flow | 46.94M | -140.08M | -1.38B | -2.35B | -2.02B | -353.71M |
| Operating Cash Flow | 257.74M | 54.75M | -1.11B | -1.50B | -1.26B | 263.63M |
| Investing Cash Flow | -167.39M | -203.49M | -248.24M | -817.65M | -841.56M | -637.95M |
| Financing Cash Flow | 303.55M | 537.67M | 1.39B | 978.31M | 2.43B | -626.90M |
RemeGen Co. Ltd. Class H Technical Analysis
Negative
119.90
Price Trends
90.69
Negative
88.86
Negative
90.19
Negative
Market Momentum
-6.04
Negative
30.27
Neutral
23.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9995, the sentiment is Negative. The current price of 119.9 is above the 20-day moving average (MA) of 73.96, above the 50-day MA of 90.69, and above the 200-day MA of 90.19, indicating a bearish trend. The MACD of -6.04 indicates Negative momentum. The RSI at 30.27 is Neutral, neither overbought nor oversold. The STOCH value of 23.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9995.
RemeGen Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$33.34B | 35.73 | 23.99% | ― | 16.65% | 0.87% | |
58 Neutral | HK$15.98B | 23.24 | 10.12% | ― | 110.05% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$60.53B | 49.36 | 42.27% | ― | 80.08% | ― | |
46 Neutral | HK$76.41B | -60.61 | -14.26% | ― | 44.03% | -108.83% | |
46 Neutral | HK$6.53B | -57.85 | -6.26% | ― | -11.65% | -169.40% | |
42 Neutral | HK$30.87B | -46.82 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:9995
RemeGen Co. Ltd. Class H
66.85
2.35
3.64%
HK:9926
Akeso, Inc.
85.50
-12.10
-12.40%
HK:9966
Alphamab Oncology
7.19
0.04
0.56%
HK:9969
InnoCare Pharma Ltd.
10.76
-2.76
-20.41%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
16.25
-6.75
-29.35%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
62.75
11.40
22.20%
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Wins Conditional China Nod for Telitacicept in IgA Nephropathy
Jun 8, 2026
RemeGen has secured conditional marketing approval from China’s National Medical Products Administration for a new indication of its biologic Telitacicept Injection to treat adult patients with primary IgA nephropathy at risk of disease prog...
RemeGen Wins NMPA Approval for New Telitacicept Indication in Sjögren’s Disease
Jun 8, 2026
RemeGen Co., Ltd. has secured approval from China’s National Medical Products Administration for a new indication of its biologic Telitacicept for Injection, allowing its use in adult patients with active Sjögren’s disease who are...
RemeGen boosts cash management with new RMB300 million SPDB wealth product
Jun 1, 2026
RemeGen Co., Ltd. has expanded its use of idle self-owned funds for short-term cash management, entering into a new SPDB Wealth Management Product Agreement No. 8 with the Shanghai Pudong Development Bank Yantai Branch on 1 June 2026. Under the la...
RemeGen Expands Use of Idle Funds in HTSC Wealth Products
May 26, 2026
RemeGen Co., Ltd. has been actively deploying part of its idle self-owned funds into wealth management products, under a board approval that allows up to RMB2.5 billion in such cash management activities. The company has entered into a series of a...
RemeGen Deploys Idle Funds Into HTSC Wealth Products in Discloseable Transaction
May 20, 2026
RemeGen Co., Ltd. has expanded its use of idle self-owned funds for cash management by purchasing a series of wealth management products from HTSC, totaling several hundred million renminbi. The purchases, approved by the board under a cash manage...
RemeGen Sets 2025 AGM to Approve Reports, Capital Changes and New Board
May 20, 2026
RemeGen Co., Ltd. has convened its 2025 annual general meeting for June 16, 2026 in Yantai, where shareholders will review the board’s work report, financial statements, full annual report and profit distribution plan for 2025, as well as de...
RemeGen Tightens Controls After Delay in Disclosing Wealth Management Deals
May 19, 2026
RemeGen Co., Ltd. has disclosed that it purchased seven wealth management products from Shanghai Pudong Development Bank between April 28 and May 13, 2026, which, when aggregated under Hong Kong listing rules, triggered disclosure obligations as a...
RemeGen Deploys Idle Cash into HTSC Wealth Products in Discloseable Deal
May 19, 2026
RemeGen Co., Ltd. has approved a cash management strategy allowing the use of up to RMB2.5 billion in idle self-owned funds to purchase wealth management products, as part of efforts to optimize returns on surplus liquidity. The company recently e...
RemeGen Launches Election for Third-Session Board as Current Term Nears Expiry
May 18, 2026
RemeGen Co., Ltd. has initiated the election process for its third board session as the term of the current board nears expiry, in line with PRC company law, applicable listing rules and its articles of association. Until new directors are approve...
RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances
May 18, 2026
RemeGen Co., Ltd. has proposed amendments to its articles of association to reflect an increase in registered capital and total issued A shares arising from attributions under its 2022 and 2023 Restricted A Share Incentive Schemes. The board has a...
RemeGen Deploys Idle Cash Into RMB453 Million HTSC Wealth Products
May 14, 2026
RemeGen Co., Ltd. has approved a cash management plan allowing the use of up to RMB2.5 billion of idle self-owned funds to purchase wealth management products, reflecting an effort to enhance returns on surplus liquidity without diverting capital ...
RemeGen Commits US$70 Million of Idle Funds to OCBC Structured Deposit
May 14, 2026
RemeGen Co., Ltd. has authorized the use of up to RMB2.5 billion in idle self-owned funds for cash management and, under this mandate, has agreed to purchase a US$70 million profit-linked structured deposit from OCBC. The medium-risk, non-principa...
RemeGen Commits RMB1.43 Billion of Idle Funds to Wealth Management Products
May 13, 2026
RemeGen Co., Ltd. has approved a cash management plan allowing the use of up to RMB2.5 billion of idle self-owned funds and up to RMB80 million of idle A-share proceeds to purchase wealth management products. In line with this plan, the company ha...
RemeGen Issues Unaudited 2026 First-Quarter Report and Cautions Investors
Apr 28, 2026
RemeGen Co., Ltd. has released its unaudited 2026 first quarterly report, prepared under PRC accounting principles for compliance with STAR Market requirements, and clarified that these figures differ from those prepared under International Financ...
RemeGen Sets Board Meeting to Approve First-Quarter 2026 Results
Apr 16, 2026
RemeGen Co., Ltd. has scheduled a board meeting for April 28, 2026, to review and approve the unaudited first-quarter results for the three months ended March 31, 2026. The company also plans to publish these results after board approval, signalin...
RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
Apr 15, 2026
RemeGen has confirmed receipt of a US$650 million upfront payment from AbbVie under their exclusive license agreement for RC148, a PD-1/VEGF targeting bispecific antibody developed by RemeGen. The deal grants AbbVie exclusive rights to develop, ma...
RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer
Apr 10, 2026
RemeGen has secured approval from China’s National Medical Products Administration for a new indication of its flagship antibody-drug conjugate Disitamab Vedotin, in combination with immunotherapy drug Toripalimab, as a first-line treatment ...
RemeGen Wins NMPA Nod to Start Clinical Trial of Bispecific ADC RC288
Apr 1, 2026
RemeGen Co., Ltd. announced that China’s National Medical Products Administration has approved the Phase I/IIa clinical trial application for RC288, a bispecific antibody-drug conjugate for injection targeting PSMA and B7H3, to be tested as ...
RemeGen Boosts 2025 Revenue as Telitacicept Wins New Approvals and NRDL Access
Mar 27, 2026
RemeGen reported strong product sales revenue of about RMB2.31 billion for 2025, up 35.8% year on year, driven mainly by robust growth from its autoimmune therapy telitacicept and oncology drug disitamab vedotin. The performance underscores the co...
RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer
Mar 23, 2026
RemeGen has obtained approval from China’s National Medical Products Administration for a new indication of its flagship drug Disitamab Vedotin to treat adult patients with unresectable or metastatic HER2-low breast cancer with liver metasta...
RemeGen Schedules March 27 Board Meeting to Approve 2025 Annual Results
Mar 17, 2026
RemeGen Co., Ltd. has scheduled a board meeting for March 27, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The board will also consider whether to recommend a dividend, a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.